Takeda takes aim at new vomiting-bug vaccine

Bloomberg has an extensive article today on Takeda's leading effort to develop a norovirus--or vomiting bug--vaccine that could prove a boon to the cruise ships and schools which are often afflicted with outbreaks. Every year about 21 million people in the U.S. are infected, and about 800 die. This experimental vaccine combines components of two types of norovirus, which Takeda believes should provide an effective guard against all the viral strains in circulation. And some analysts believe it could be worth up to $400 million a year in revenue if Takeda can get an approval ahead of its rivals. Story | More from FierceVaccines

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.